Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports.
Mosaic ImmunoEngineering Stock Performance
OTCMKTS:CPMV opened at $0.06 on Friday. The company has a market capitalization of $441,640.00, a price-to-earnings ratio of -0.68 and a beta of -0.82. Mosaic ImmunoEngineering has a one year low of $0.05 and a one year high of $1.05. The stock has a 50-day simple moving average of $0.58 and a 200 day simple moving average of $0.60.
About Mosaic ImmunoEngineering
Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.
Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.
See Also
- Five stocks we like better than Mosaic ImmunoEngineering
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
- MarketBeat Week in Review – 08/10 – 08/14
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
